Form 4: Allogene Therapeutics Director Receives Significant Equity Grant

Allogene Therapeutics, Inc. Director Elizabeth A. Barrett was granted 95,400 Restricted Stock Units, aligning her interests with long-term shareholder value.

Summary

• Elizabeth A. Barrett, a Director of Allogene Therapeutics, Inc. (ALLO), was granted 95,400 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Company's Common Stock.
• The RSUs are scheduled to vest in two successive equal semi-annual installments over a one-year period, commencing from the grant date of June 18, 2025, subject to Ms. Barrett's continued service through each vesting date.
• Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs, in accordance with the Company's Non-Employee Director Compensation Policy, until the earlier of 30 days following her separation from the Board or a change in control of the Company.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning incentives but does not indicate significant operational or financial news that would dramatically alter the company's outlook.

Positives

• The grant of Restricted Stock Units to a director aligns their financial interests directly with the long-term performance and shareholder value of Allogene Therapeutics, Inc.
• Ms. Barrett's election to defer the receipt of common stock upon vesting demonstrates a commitment to the company's long-term success and potentially signals confidence in its future prospects.

Risks

• The vesting of the Restricted Stock Units is contingent upon Ms. Barrett's continued service as a director, meaning the shares will not be received if her service terminates before vesting dates.
• The ultimate value of the RSU grant is dependent on the future market price of Allogene Therapeutics' common stock, exposing the value to market fluctuations.

Future Outlook

The Restricted Stock Units are set to vest in two equal semi-annual installments over a one-year period from the grant date of June 18, 2025, contingent on Ms. Barrett's continued service. The deferral of stock receipt by Ms. Barrett indicates a long-term perspective on her investment in the company.

Management Comments

• Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Company's Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company.

Industry Context

The grant of Restricted Stock Units is a common and standard practice for compensating non-employee directors in the biotechnology and pharmaceutical industries. This method is widely used to align the interests of directors with those of shareholders, encouraging long-term commitment and performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for director compensation is a standard practice across publicly traded companies, particularly prevalent in the biotech sector, aligning director incentives with shareholder value.
• The vesting schedule of two semi-annual installments over one year is a typical structure for such equity grants, designed to retain talent and encourage sustained engagement.
• The deferral option for stock receipt is also a common feature in director compensation policies, offering flexibility and potential tax benefits to the recipient while signaling long-term commitment to the company.

Related Party Transactions

• Grant of 95,400 Restricted Stock Units to Elizabeth A. Barrett, a Director of Allogene Therapeutics, Inc., as part of her compensation package.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially fostering decisions that enhance long-term stock value.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The Restricted Stock Units will vest in two equal semi-annual installments over the one-year period measured from the grant date of June 18, 2025.
• Ms. Barrett will receive the underlying Common Stock upon vesting, deferred until her separation from the Board or a change in control of the Company.

Key Dates

Recommendation

Keywords

Allogene Therapeutics, ALLO, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Insider Transaction, SEC Form 4, Corporate Governance